Hydroxyurea Therapy Mobilises Arachidonic Acid from Inner Cell Membrane Aminophospholipids in Patients with Homozygous Sickle Cell Disease
Table 5
Fatty acid composition of red blood cell ethanolamine phosphoglycerides of HU-untreated () and treated () HbSS sickle cell patients and HbAA healthy controls ().
Fatty acids
HbSS (untreated)
HbSS (treated)
HbAA (healthy control)
16:0
12.8 ± 1.3
12.8 ± 1.3
12.8 ± 1.2
18:0
7.9 ± 0.9
8.7 ± 1.4×××
6.0 ± 0.7+++
20:0
0.1 ± 0.02
0.08 ± 0.03
0.06 ± 0.03
22:0
0.03 ± 0.01***
0.07 ± 0.02
0.08 ± 0.04+++
24:0
0.06 ± 0.03*
0.08 ± 0.02×××
0.06 ± 0.02
∑saturates
21.02 ± 1.0
21.9 ± 1.5×××
19.1 ± 1.1+++
16:1n-7
0.1 ± 0.03***
0.1 ± 0.02
0.1 ± 0.04+++
18:1n-7
0.9 ± 0.2
1.2 ± 0.8
0.9 ± 0.1
18:1n-9
13.1 ± 1.2
12.1 ± 1.1
12.9 ± 0.7
24:1n-9
tr.
tr.
tr.
∑monoenes
14.0 ± 1.3
13.2 ± 1.1
13.9 ± 1.0
18:2n-6
4.9 ± 0.7
4.9 ± 0.9×××
6.7 ± 0.9+++
18:3n-6
0.2 ± 0.05***
0.04 ± 0.01
0.04 ± 0.01+++
20:2n-6
0.6 ± 0.2
0.5 ± 0.1
0.5 ± 0.1
20:3n-6
1.4 ± 0.3
1.3 ± 0.2×××
1.0 ± 0.1+++
20:4n-6
24.0 ± 1.1*
22.9 ± 1.2××
24.8 ± 1.5
22:4n-6
10.8 ± 0.1*
9.89 ± 1.0×××
8.6 ± 0.7+++
22:5n-6
2.6 ± 0.4*
2.2 ± 0.5
1.9 ± 0.3+++
∑metabolites
39.4 ± 1.3***
36.8 ± 2.2
36.8 ± 1.7+++
∑n-6
44.3 ± 1.5***
41.4 ± 2.5×
43.9 ± 1.8
18:3n-3
0.08 ± 0.04
0.08 ± 0.02
0.1 ± 0.03
20:5n-3
0.11 ± 0.03*
0.15 ± 0.05×××
0.23 ± 0.06+++
22:5n-3
1.7 ± 0.3
1.6 ± 0.3
1.7 ± 0.2
22:6n-3
2.7 ± 0.4
2.9 ± 0.88
3.2 ± 0.6+
∑metabolites
4.5 ± 0.5
4.6 ± 1.1
5.1 ± 0.7+
∑n-3
4.6 ± 0.5
4.7 ± 1.1
5.2 ± 0.7+
N6/N3
9.8 ± 1.4
9.3 ± 2.34
8.5 ± 1.3+
tr.: trace. HU-untreated versus treated HbSS patients: *, **, ***. HU-untreated HbSS patients versus HbAA healthy controls: +, ++, +++. HU-treated versus HbAA healthy controls: ×, ××, ×××.
